Please assess the completion status of the following clinical trial:

Trial Title: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group Performance Status of 0 to 2~* Not eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplant~* Eligible for and agree to BM aspirate prior to treatment start~* Measurable disease M component in serum (≥ 0.5 g/dL) and/or urine (≥ 0.2 g excreted in a 24 hour collection sample)~* Must have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or those who are double refractory to a PI and an immunomodulatory agent and have demonstrated disease progression (DP) on or within 60 days of completion of the last therapy; participants previously treated with an alkylating agent, in addition to an IMiD or proteasome inhibitor, are allowed to enroll in the trial~* Participants must have adequate liver, kidney, and bone morrow function~* Participants with a history of chronic heart failure must have cardiac ECHO indicating left ventricular ejection fraction (LVEF) ≥ 45% within 21 days prior to first dose of study drug~* Participants in the combination therapy arms must be eligible to receive pomalidomide/dexamethasone, bortezomib/dexamethasone or lenalidomide/dexamethasone or other approved agents per current prescribing information for MM.~* Participants who will receive combination therapy with Pomalidomide/Dexamethasone must have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy~Exclusion Criteria:~* Received anti-cancer therapy including chemotherapy, immunotherapy, radiation, biologic, any investigational therapy or herbal therapy within a period of 21 days prior to the first dose of ABBV-838, and have unresolved toxicities ≥ grade 2~* Concurrent metastatic solid tumors~* Non-Measurable M Protein (serum or urine) and measurable sFLC (\< 100 mg/mL)~* Major surgery within 21 days prior to the first dose of ABBV-838~* Clinically significant uncontrolled condition(s) including but not limited to the following:~Grade ≥ 3 peripheral neuropathy or grade 2 peripheral neuropathy with pain Uncontrolled hypercalcemia Active uncontrolled infection Symptomatic congestive heart failure Unstable angina pectoris or cardiac arrhythmia Psychiatric illness/social situation that would limit compliance with the study~* Major immunologic reaction to any IgG containing agent or auristatin based agent~* Participants who are taking strong CYP3A4 inhibitors~* Positive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or C~* Corneal pathology that would limit evaluation of loss in visual acuity associated with corneal deposits.~* Prior exposure to pomalidomide for subjects enrolling in the pomalidomide/dexamethasone combination arm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABBV-838 dose escalation (Type: EXPERIMENTAL): Varying doses of ABBV-838
- ABBV-838 plus pomalidomide/dexamethasone (Type: EXPERIMENTAL): ABBV-838 to be evaluated with pomalidomide/dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).